Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and potential commercialization of small molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Headquartered in Amsterdam, Netherlands, with operations in Halle (Saale) and Munich, Germany, the company focuses on orally available inhibitors targeting glutaminyl cyclases QPCT and QPCTL to address inflammatory and fibrotic diseases. Its lead candidate, varoglutamstat, shows promise in stage 3b and worse diabetic kidney disease (DKD), demonstrating long-term stabilization or improvement in estimated glomerular filtration rate (eGFR) from prior Phase 2 studies in Alzheimer's disease, prompting a strategic pivot from neurodegeneration. Vivoryon is preparing a Phase 2b study in DKD, subject to funding or partnerships, while advancing preclinical candidates like VY2149, a next-generation QPCT/L inhibitor, and Meprin protease inhibitors for kidney disease, fibrosis, and cancer. The pipeline also includes antibody approaches and oncology combinations, supported by a robust intellectual property portfolio of over 400 patents. Vivoryon aims to generate revenues through licensing or commercialization, targeting high unmet needs in chronic kidney and liver conditions.